📰 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and

📰 Non-Narcotic Analgesics Allergy Labels Linked to Adverse Maternal and Fetal Outcomes Increased rates of NICU admission, preterm birth, eclampsia and additional adverse outcomes were shown for mothers with this allergy label and their infants MILWAUKEE, Feb. 21, 2026

📰 TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR

📰 Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more Welcome back to another edition of Endpoints Weekly! For those that had time off for Presidents’ Week, we hope you had a restful vacation. If you missed any

📰 Vanda gets FDA approval for ‘franchise-extending’ antipsychotic The FDA approved Vanda Pharmaceuticals’ drug Bysanti for schizophrenia and for the acute treatment of manic or mixed episodes related to bipolar I disorder. Bysanti is an active metabolite of Vanda’s currently

📰 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing,

📰 Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin

📰 Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc.

📰 TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction

📰 Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or

📰 Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage

📰 aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) via GlobeNewsWire - Pharma 🔗 https://t.co/kngdULKdBF 📊 https://t.co/oe3y72qefO #biotech #pharma

📰 Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates 2025 Total Revenue of $634M, up 17% Year-over-Year at CER via GlobeNewsWire - Biotech 🔗 https://t.co/NohcMlySxv 📊 https://t.co/oe3y72qefO #biotech

📰 Science Corp. and Neurosoft Bioelectronics Announce Novel BCI Ecosystem Partnership ALAMEDA, Calif. & GENEVA--(BUSINESS WIRE)--Science Corporation, the pioneering full-stack neural engineering company focused on restoring and extending life, and Neurosoft Bioelectronics, a

📰 U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE

📰 Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option via GlobeNewsWire - Pharma

📰 Ionis scraps Alzheimer’s drug for people with Down syndrome Ionis Pharmaceuticals has ended the development of a potential medicine for people with Down syndrome who are at risk of Alzheimer’s disease, Endpoints News has learned. A spokesperson for the California biotech

📰 Grail's cancer test faces new uncertainty after UK study After mounting a comeback with fresh capital and a flashy partnership, cancer testing firm Grail once again faces major questions over the future of its blood test that screens for dozens of cancers. The company' ...

📰 Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat Avian Flu in Partnership with Canadian Food Inspection Agency SALT LAKE CITY--(BUSINESS WIRE)-- #AvianInfluenza--Seek Labs received a $2M USDA APHIS grant to develop

📰 Cambridge Cognition Partners With Ivory to Scale Early Cognitive Screening With CANTAB Pathway™ in India BENGALURU, India & CAMBRIDGE, England--(BUSINESS WIRE)--Cambridge Cognition Holdings plc ("Cambridge Cognition") (AIM: COG), the neuroscience technology company